Healthy
Conditions
Keywords
Healthy, TMC278, Human Immunodeficiency Virus Type 1, HIV-1, Pharmacokinetics, Ex-vivo pharmacodynamics
Brief summary
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278 long acting (slowly effective after initial dosage and maintaining its effects over a long period of time) when administered as an intramuscular (ie, in to the muscle) injection in adult participants who are seronegative for human immunodeficiency virus type 1 (HIV-1).
Detailed description
This is an open-label (all people know the identity of the intervention), multi-arm (more than one treatment group), dose-ranging study (clinical study where different doses of study medication are tested against each other) to evaluate the safety, acceptability, pharmacokinetics, and ex vivo pharmacodynamics of a single and multiple intramuscular injections of long acting TMC278 to human immunodeficiency virus type 1 (HIV-1) seronegative (having a negative serum reaction) male and female participants. The study consists of 3 phases including screening phase, treatment phase, and the follow up phase (approximately 4 to 6 months after the first dose of study medication). In treatment phase, enrolled participants will be divided in to 2 arms, ie, Arm A (female participants) which will be further divided in to Arm 1A, Arm 2A, Arm 3A, Arm 4A, and Arm 5A with 12 female participants per arm; and Arm B (male participants) which will be further divided in to Arm 1B, Arm 2B, Arm 3B, Arm 4B, and Arm 5B with 6 male participants per arm. Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, physical examination, and vital signs which will be monitored throughout the study. The total duration of study for each participant will be approximately 5 to 7 months.
Interventions
DRUGTMC278, Long acting (LA)
TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Human immunodeficiency virus type 1 (HIV-1) seronegative at screening and enrollment * Not pregnant or breastfeeding females * Agrees to protocol-defined method of contraception * Abstinence from insertion of anything in rectum (eg, medication, enema, penis, or sex toy) for 72 hours before and 72 hours after each rectal biopsy visit * Abstinence from insertion of anything in vagina (eg, tampon, medication, douche, penis, or sex toy) for 72 hours before and 72 hours after each cervical and vaginal biopsy visit
Exclusion criteria
* Post-exposure prophylaxis for HIV exposure within 6 months prior to screening and known HIV-infected partners * Use of systemic immunomodulatory medications within the 4 weeks prior to the enrollment * Use of vaginally or rectally administered medications or products (including condoms) containing Nonoxynol-9 (N-9) within the 4 weeks prior to the enrollment * Abnormalities of the cervical, vaginal, or colorectal mucosa, or significant symptom(s), which in the opinion of the clinician represents a contraindication to protocol-required biopsies * History of recurrent urticaria * History of or electrocardiogram demonstrating prolonged QT interval * History of significant gastrointestinal bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 280 days |
| Number of participants who would consider using long acting TMC278 for Human immunodeficiency virus (HIV) prevention in the future | Up to 280 days |
Secondary
| Measure | Time frame |
|---|---|
| TMC278 concentration in vaginal fluid | Up to 280 days |
| TMC278 concentration in rectal fluid | Up to 280 days |
| TMC278 concentration in plasma | Up to 280 days |
| TMC278 concentration in vaginal tissue | Up to 280 days |
| TMC278 concentration in rectal tissue | Up to 280 days |
| TMC278 concentration in cervical tissue | Up to 280 days |
| TMC278 concentration in endocervical fluid | Up to 280 days |
Countries
United States
Outcome results
None listed